A Phase I Study of LFA102 in Japanese Patients

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

This study will evaluate safety and tolerability to determine the MTD/RD.

Phase 1

Novartis Pharmaceuticals